Acridine

Acridine

SCHEMBL22168564

Nc1nc(N)nc(N)n1.c1ccc2nc3ccccc3cc2c1

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.75
HPGD P15428 5/20 0.75
MAPT P10636 5/20 0.75
GLA P06280 3/20 0.75
ACHE P22303 3/20 0.75
HTR3A P46098 1/20 0.65
KDM4E B2RXH2 5/20 0.57
GAA P10253 5/20 0.57
KMT2A Q03164 4/20 0.57
POLB P06746 3/20 0.57
NPC1 O15118 2/20 0.57
LMNA P02545 2/20 0.57
RAB9A P51151 2/20 0.57
PTBP1 P26599 1/20 0.57
RCE1 Q9Y256 1/20 0.57
MEN1 O00255 2/20 0.52
USP2 O75604 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acridine SCHEMBL1772714 0.87 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL4972293 0.87 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL3045498 0.87 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL29352289 0.87 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL8339 0.87 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL10827474 0.85 ALDH1A1 (0.75) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL28646458 0.84 ALDH1A1 (0.83) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL17141399 0.84 ALDH1A1 (0.83) ALDH1A1HPGDMAPTGLAACHE
Anthracene SCHEMBL9879830 0.84 MAPT (0.94) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL1551975 0.84 ALDH1A1 (0.94) ALDH1A1HPGDMAPTGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3750528-A1 COMPOSITIONS FOR TREATING DYSTROPHIES AND MYOTONIA Nexien Biopharma, Inc. (US) 2020-12-16 EP disclosed
US-10702495-B2 Method and compositions for treating dystrophies and myotonia NEXIEN BIOPHARMA, INC. (US) 2020-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10702495-B2 Method and compositions for treating dystrophies and myotonia MYOF, MYH2, MYLK2 ALDH1A1 3113/4885HPGD 2714/4885MAPT 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.